During her doctoral thesis (2011-2016), Kim De Veirman studied the interactions between the tumor and its environment, which leads to survival of the MM cell. Her doctoral work identified novel therapeutic targets to help treat MM patients. For the significant scientific contributions of her work, she was awarded the Prijs Dr Karel-Lodewijk Verleysen by the "Koninklijke Academie voor Geneeskunde" of Belgium.
Moreover, for her ongoing research whereby she aims to eliminate residual cancer cells by using specific nanobodies, she was also rewarded the Brian D. Novis Research Award (International Myeloma Foundation, USA) and the Abstract Achievement award at the ‘American Society of Hematology’ meeting in Orlando, Florida.